Skip Navigation

Cardiovascular Research 1997 33(3):693-697; doi:10.1016/S0008-6363(96)00222-2
© 1997 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Samani, N. J.
Right arrow Articles by Lodwick, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samani, N. J.
Right arrow Articles by Lodwick, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Glycoprotein IIIa polymorphism and risk of myocardial infarction

Nilesh J. Samani* and David Lodwick

Divisions of Cardiology and Medicine, Department of Medicine, University of Leicester, Leicester, UK

Objectives: To prospectively investigate whether the PlA2 variant of the platelet adhesion molecule glycoprotein IIIa influences the risk of myocardial infarction. Background: The platelet glycoprotein IIb/IIIa receptor plays an important role in platelet aggregation. The IIIa polypeptide is polymorphic due to a single base change at position 1565 resulting in either proline PlA1 or leucine PlA2 at position 33 in the protein. It has recently been reported that the PlA2 variant may be strongly associated with the risk of acute coronary syndromes, particularly in younger subjects. Methods: PlA genotypes of 242 prospectively collected cases of first myocardial infarction admitted to our Coronary Care Unit were compared with those of 209 community-based control subjects. Results: We found no difference in either PlA genotype (P = 0.65) or allele (P = 0.64) frequencies between cases and controls. The PlA2 allele frequency was 18.2 and 19.4% in cases and controls, respectively. The age- and sex-stratified odds ratio for risk of myocardial infarction associated with the PlA2 allele was 0.89 (95% CI 0.58–1.37, P = 0.65) and remained non-significant when the analysis was confined to subjects under the age of 60 (odds ratio 0.77, 95% CI 0.38–1.56, P = 0.44). There was no interaction between PlA2 and other coronary risk factors. For cases, the age at myocardial infarction was not different between those carrying the PlA2 allele and those not (66.3 ± 10.8 vs. 65.6 ± 11.7 years, P = 0.63). Conclusions: We conclude that, in our subjects, the PlA2 variant of platelet glycoprotein IIIa is not an important risk factor for myocardial infarction.

KEYWORDS Myocardial infarction; Platelets; Integrins; Glycoprotein IIb/IIIa; Human; Genetics; DNA polymorphism


* Corresponding author. Department of Cardiology, Clinical Sciences Wing, Glenfield General Hospital, Groby Road, Leicester LE3 9QP, UK. Tel.: (+44-116) 2563038; Fax: (+44-116) 2875792.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
E. Papp, V. Havasi, J. Bene, K. Komlosi, L. Czopf, E. Magyar, C. Feher, G. Feher, B. Horvath, Z. Marton, et al.
Glycoprotein IIIA Gene (PlA) Polymorphism and Aspirin Resistance: Is There Any Correlation?
Ann. Pharmacother., June 1, 2005; 39(6): 1013 - 1018.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. P. Schulman
Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes
JAMA, October 20, 2004; 292(15): 1875 - 1882.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. B. Braunstein, D. W. Kershner, P. Bray, G. Gerstenblith, S. P. Schulman, W. S. Post, and R. S. Blumenthal
Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women
Chest, March 1, 2002; 121(3): 906 - 920.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Benze, J. Heinrich, H. Schulte, S. Rust, U. Nowak-Gottl, M.-C. Tataru, E. Kohler, G. Assmann, and R. Junker
Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men
Eur. Heart J., February 2, 2002; 23(4): 325 - 330.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Feng, K. Lindpaintner, M. G. Larson, C. J. O'Donnell, I. Lipinska, P. A. Sutherland, M. Mittleman, J. E. Muller, R. B. D'Agostino, D. Levy, et al.
Platelet Glycoprotein IIIa PlA Polymorphism, Fibrinogen, and Platelet Aggregability: The Framingham Heart Study
Circulation, July 10, 2001; 104(2): 140 - 144.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Bennett, F. Catella-Lawson, A. R. Rut, G. Vilaire, W. Qi, S. C. Kapoor, S. Murphy, and G. A. FitzGerald
Effect of the PlA2 alloantigen on the function of {beta}3-integrins in platelets
Blood, May 15, 2001; 97(10): 3093 - 3099.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D.H Walter, V Schachinger, M Elsner, S Mach, S Dimmeler, W Auch-Schwelk, and A.M Zeiher
Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2allele of the platelet glycoprotein IIIa gene
Eur. Heart J., April 1, 2001; 22(7): 587 - 595.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. Mikkelsson, M. Perola, P. Laippala, A. Penttila, and P. J. Karhunen
Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death
J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1317 - 1323.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Kastrati, W. Koch, M. Gawaz, J. Mehilli, C. Bottiger, K. Schomig, N. von Beckerath, and A. Schomig
PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement
J. Am. Coll. Cardiol., July 1, 2000; 36(1): 84 - 89.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. A. Lane and P. J. Grant
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Blood, March 1, 2000; 95(5): 1517 - 1532.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feng, K. Lindpaintner, M. G. Larson, V. S. Rao, C. J. O'Donnell, I. Lipinska, C. Schmitz, P. A. Sutherland, H. Silbershatz, R. B. D'Agostino, et al.
Increased Platelet Aggregability Associated With Platelet GPIIIa PlA2 Polymorphism : The Framingham Offspring Study
Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 1142 - 1147.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kastrati, A. Schomig, M. Seyfarth, W. Koch, S. Elezi, C. Bottiger, J. Mehilli, K. Schomig, and N. von Beckerath
PlA Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement
Circulation, March 2, 1999; 99(8): 1005 - 1010.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Gonzalez-Conejero, M. L. Lozano, J. Rivera, J. Corral, J. A. Iniesta, J. M. Moraleda, and V. Vicente
Polymorphisms of Platelet Membrane Glycoprotein Ibalpha Associated With Arterial Thrombotic Disease
Blood, October 15, 1998; 92(8): 2771 - 2776.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.